Dalantercept plus axitinib fails to improve progression-free survival in people with kidney cancer
The development of dalantercept, an anaplastic lymphoma kinase 1 (ALK1) [...]
The development of dalantercept, an anaplastic lymphoma kinase 1 (ALK1) [...]